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Therapy for BK virus (BKV)eassociated hemorrhagic cystitis (BKV-HC) is limited after hematopoietic stem cell
transplantation (HSCT). We examined whether choreito, a formula from Japanese traditional Kampo medi-
cine, is effective for treating BKV-HC. Among children who underwent allogeneic HSCT between October
2006 and March 2014, 14 were diagnosed with BKV-HC (median, 36 days; range, 14 to 330 days) after HSCT,
and 6 consecutive children received pharmaceutical-grade choreito extract granules. The hematuria grade
before treatment was signiﬁcantly higher in the choreito group than in the nonchoreito group (P ¼ .018). The
duration from therapy to complete resolution was signiﬁcantly shorter in the choreito group (median, 9 days;
range, 4 to 17 days) than in the nonchoreito group (median, 17 days; range, 15 to 66 days; P ¼ .037). In 11
children with macroscopic hematuria, the duration from treatment to resolution of macroscopic hematuria
was signiﬁcantly shorter in the choreito group than in the nonchoreito group (median, 2 days versus 11 days;
P ¼ .0043). The BKV load in urine was signiﬁcantly decreased 1 month after choreito administration. No
adverse effects related to choreito administration were observed. Choreito may be a safe and considerably
promising therapy for the hemostasis of BKV-HC after HSCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hemorrhagic cystitis (HC) is a severe complication in
patients undergoing hematopoietic stem cell transplantation
(HSCT), resulting in signiﬁcant morbidity, such as nephrop-
athy and renal failure, prolonged hospitalization, and pro-
longed blood transfusion requirement [1,2]. Effects on
mortality have also been reported in children undergoing
HSCT [3]. Early-onset HC occurs within 1 week after HSCT
and is mostly a symptom of regimen-related toxicity. Late-
onset HC usually occurs after engraftment and is associated
with viral infections, including those caused by the human
polyomavirus BK (BKV), polyomavirus JC, adenovirus (AdV),
and cytomegalovirus (CMV) [4]. BKV is the most frequent
cause of late-onset HC and affects 5.3% to 21.2% of children
undergoing HSCT [5-9]. BKV viruria is detected by real-time
quantitative PCR (RT-PCR) in all patients with BKV-HC. A BKV
load of more than 106 copies/mL in urine may be associateddgments on page 324.
requests: Seiji Kojima, MD, PhD,
University Graduate School of Medicine,
ya, Aichi, 466-8550 Japan.
agoya-u.ac.jp (S. Kojima).
14.10.018
ty for Blood and Marrow Transplantation.with a high risk of developing HC after HSCT [5]. However,
asymptomatic BK viruria is detected in 50% to 100% of
patients after HSCT [5,7,10], implicating that the presence of
BKV viruria alone does not explain the pathogenesis of HC.
High BKV viremia (103 copies/mL) is a better predictor of
BKV-HC after HSCT, with a reported speciﬁcity of 93% [8].
Children with high BKV viremia (104 copies/mL) are at a
higher risk of developing severe HC [6].
The standard treatment for BKV-HC has not been estab-
lished [2]. Supportive therapy is provided to patients with
mild BKV-HC, including intravenous hydration, bladder irri-
gation, and symptomatic relief treatment, such as the use of
analgesics. Patients with severe BKV-HC require additional
therapy. The current ﬁrst line BKV-oriented therapy is
intravenous cidofovir; however, its efﬁcacy remains contro-
versial [2]. Alternative strategies include intravesical instil-
lation of cidofovir [2,7], hyperbaric oxygen therapy [11],
leﬂunomide, and ﬂuoroquinolone [12]; however, their effect
is limited [13]. Invasive intervention such as vascular
embolization or cystectomy may be necessary in uncontrol-
lable HC.
Choreito is a formula derived from Japanese traditional
Kampomedicine. The indication for choreito in the context of
N. Kawashima et al. / Biol Blood Marrow Transplant 21 (2015) 319e325320Kampo medicine is “dampness-heat” in the lower abdomen,
the characteristic symptoms of which include dysuria, heat
in the lower abdomen, and thirst. All these symptomsmay be
caused by inﬂammation and blood clots in the bladder. Based
on this indication, choreito has been administered to pa-
tients with acute simple cystitis and urolithiasis, and its
effectiveness has been conﬁrmed [14]. Recently, choreitowas
successfully used to treat massive gross hematuria with clot
retention in the bladder in a child with refractory acute
lymphoblastic leukemia [14]. At present, choreito is covered
by the national health insurance and is widely used for
genitourinary symptoms in Japan.
Symptoms leading to the traditional use of choreito
appear to overlap with symptoms associated with BKV-HC;
indeed, some children receive choreito for HC. In this
study, we retrospectively analyzed BKV-HC in children
undergoing HSCT and evaluated the efﬁcacy of choreito
treatment.
PATIENTS AND METHODS
Deﬁnition
HC was deﬁned as microscopic (blood in urine graded 1þ or more) or
macroscopic hematuria combined with dysuria, pollakisuria, urinary ur-
gency, and/or the sensation of residual urine in the absence of bacteria in
urine as observed by culture [9]. BKV-HC was deﬁned as the association of
HC with BKV viruria and/or viremia. HC was graded according to the widely
used criteria [15]. Grade I is deﬁned as microscopic hematuria, grade II as
macrohematuria, grade III as macroscopic hematuria with clots, and grade
IV as macroscopic hematuria with renal or bladder dysfunction. The onset of
BKV-HC was deﬁned as the ﬁrst day when patients presented with urinary
symptoms, and complete resolution (CR) of HC was deﬁned as blood in urine
( or  for hemoglobin) and disappearance of dysuria, pollakisuria, urinary
urgency, and the sensation of residual urine related to HC.
Patient Inclusion Criteria of BKV-HC and Choreito Administration
Among the children (18 years old) who received allogeneic HSCT be-
tween October 2006 andMarch 2014 in Nagoya University Hospital, 14 were
diagnosed with BKV-HC and included in the study. Their medical records
were retrospectively analyzed. Patient characteristics are listed in Table 1.
Intravenous ﬂuids corresponding to 2.5 to 3.0 L/m2/day with forced alka-
linized diuresis were administered during conditioning, and patients treated
with cyclophosphamide received prophylactic mesna for the prevention of
HC. All the patients received acyclovir for herpes prophylaxis and weekly
intravenous immunoglobulin for viral prophylaxis. Tacrolimus was intra-
venously administered for graft-versus-host disease (GVHD) prophylaxis in
patients receiving HSCT from an unrelated donor. Cases of engraftment
syndrome and GVHD were treated by methylprednisolone, followed by
salvage therapies in nonresponding patients. Six children with BKV-HC
diagnosed after March 2013 received a pharmaceutical-grade medicine,
choreito extract granules (Tsumura & Co., Tokyo, Japan) with a dose of .2 g/kgTable 1
Patient Demographics of BKV-HC after HSCT
UPN Choreito Treatment Age, yr Sex Diagnosis Clinical Status P
1 No 15.3 M AA Non CR C
2 No 16.0 M AA Non CR F
3 No 12.3 M B-ALL CR1 M
4 No 11.8 M CML CyCR F
5 No 7.1 F T-ALL CR2 F
6 No 5.7 M NB CR1 F
7 No 15.4 M CMML Non CR F
8 No 7.8 M B-ALL CR2 M
9 Yes 14.3 M AA Non CR F
10 Yes 5.4 M MDS Non CR F
11 Yes 10.1 F AA Non CR F
12 Yes 12.2 F CMML Non CR F
13 Yes 6.8 M B-ALL CR2 M
14 Yes 7.5 M MDS Non CR F
UPN indicates unique patient number; M, male; AA, aplastic anemia; Cy, cyclop
unrelated; BM, bone marrow; FK, tacrolimus; sMTX, short course of methotrexat
kemia; MEL, melphalan; CML, chronic myelogenous leukemia; CyCR, cytological c
blastoma; CB, cord blood; CMML, chronic myelomonocytic leukemia; MDS, myeloper os daily in 3 divided doses (maximum, 7.5 g/day). Cidofovir and choreito
were administered at the onset of macroscopic hematuria. Because it is not
currently approved for clinical use in Japan, cidofovir was administered only
to those who provided written informed consent.
Quantiﬁcation of BKV DNA
Children undergoing HSCT were weekly monitored for plasma CMV,
human herpesvirus 6, and Epstein-Barr virus, and thosewhomet the criteria
for HC underwent additional viral workup, including analysis for BKV, pol-
yomavirus JC, and AdV. For 2 patients with BKV diagnosed before December
2009, BKV had been detected in urine by qualitative PCR. This qualitative
PCR could not detect BKV in patients without HC. After January 2010, viruses
were monitored by multiplex RT-PCR for quantiﬁcation of DNA from BKV,
polyomavirus JC, and AdV, as described previously [16]. In April 2010, BKV
RT-PCRwas used to screen all 30 hospitalized childrenwith various hemato-
oncological diseases who had neither HC-related symptoms nor abnormal
urinalysis. All patients provided informed consent for viral PCR workup in
accordance with the Declaration of Helsinki. This retrospective analysis was
approved by the ethics committee of Nagoya University Graduate School of
Medicine.
Statistical Analysis
Statistical analysis was performed using the Fisher’s exact test for cat-
egorical variables and the Mann-Whitney’s U test for continuous variables.
The Wilcoxon signed-rank test was used for paired samples. Odds ratios
with conﬁdence intervals were estimated by the logistic regression. A
probability (P) value <.05 was considered to indicate statistical signiﬁcance.
All statistical analyses were conducted using JMP Pro 11.0.0 (SAS Institute
Inc., Cary, NC).
RESULTS
BKV Screening in Hemato-oncological Patients without
Genitourinary Symptoms
All children with hemato-oncological disorders hospi-
talized in the same ward were screened for BKV viruria for
the purpose of surveillance. BKV viruria was detected in 5
(17%) of 30 hospitalized children with various hemato-
oncological diseases who had neither HC-related symp-
toms nor abnormal urinalysis. The median urine BKV load in
childrenwith asymptomatic viruria was 1.3  106 copies/mL
(range, 3.5  103 to 2.0  109 copies/mL), which was
signiﬁcantly lower than that in children with BKV-HC (me-
dian, 5.4  1010 copies/mL; range, 8.3  107 to 1.5  1011
copies/mL; P ¼ .0021).
Patient Characteristics of Cases with BKV-HC after HSCT
Table 1 summarizes the patient characteristics of 14
children who underwent HSCT and later developed BKV-HC.
In patients 1 and 2, BKV was detected in urine by qualitativereconditioning Regimen Stem Cell Source GVHD Prophylaxis
Y þ ATG þ TBI 5 Gy UR-BM FK þ sMTX
LU þ CY þ Campath þ TBI 3 Gy UR-BM FK þ sMTX
EL þ TBI 12 Gy UR-BM FK þ sMTX
LU þ MEL þ TBI 3 Gy UR-BM FK þ sMTX
LU þ MEL þ ATG þ TBI 12 Gy Haplo FK þ sMTX
LU þ MEL þ TBI 2 Gy UR-CB FK þ sMTX
LU þ MEL þ ATG þ TBI 5 Gy Haplo FK þ sMTX
EL þ ATG þ TBI 12 Gy UR-BM FK þ sMTX
LU þ MEL þ ATG þ TBI 3 Gy Haplo FK þ sMTX
LU þ MEL þ ATG þ TBI 5 Gy Haplo FK þ sMTX
LU þ MEL þ ATG þ TBI 5 Gy Haplo FK þ sMTX
LU þ MEL þ ATG þ TBI 5 Gy Haplo FK þ sMTX
EL þ TBI 12 Gy UR-BM FK þ sMTX
LU þ MEL þ ATG þ TBI 5 Gy Haplo FK þ sMTX
hosphamide; ATG, antithymocyte globulin; TBI, total body irradiation; UR,
e; FLU, ﬂudarabine; Campath, alemtuzumab; ALL, acute lymphoblastic leu-
omplete remission; F, female; Haplo, haploidentical transplant; NB, neuro-
dysplastic syndrome.
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N. Kawashima et al. / Biol Blood Marrow Transplant 21 (2015) 319e325 321PCR; therefore, other agents including preconditioning could
have contributed to HC. Six of the 14 children received
choreito because of BKV-HC. All patients were older than 5
years (median, 11 years; range, 5.4 to 16 years). Antithymo-
globulin or alemtuzumab was administered to 10 of 14
children (71%) as a preconditioning. Notably, all the children
received total body irradiation with various doses.
Children were diagnosed with BKV-HC at a median 36
days (range, 14 to 330 days) (Table 2) after HSCT. Six of 14
patients (43%) had grade II to IV acute GVHD, and 11 of 14
(79%) received steroids for treatment of engraftment syn-
drome and/or acute GVHD before being diagnosed with BKV-
HC. Three children with acute GVHD grade III or IV received
intensiﬁed immunosuppressive treatment for steroid-
resistant GVHD; 1 received inﬂiximab and the other 2
received inﬂiximab, basiliximab, and mesenchymal stem
cells. All 3 responded well to additional therapy for acute
GVHD. Concomitant AdV viruria was detected in 2 of 14
children (14%), and 12 of 14 children (86%) developed CMV
and/or Epstein-Barr virus infection after HSCT. AdV titers in
the urine were 2.6  108 copies/mL in patient 3 and 1.8  108
copies/mL in patient 7 at the time of diagnosis. CMV viruria
was not detected in any of these 14 children when BKV-HC
was diagnosed. Six children were receiving gancyclovir
and/or foscarnet for CMV reactivation at the time of BKV-HC
diagnosis.
Treatment for BKV Cystitis with Choreito
Six of 14 children with BKV-HC diagnosed after October
2013 received choreito (Tables 1 to 3). All 6 fulﬁlled the
Kampo indication for receiving choreito (“lower energizer
dampness-heat” in patients 9, 11, 12, 13, and 14, and “heat
binding in the lower energizer” in patient 10). Patient char-
acteristics, including age at HSCT, sex, underlying disease,
engraftment syndrome, acute GVHD frequency and grade,
immunosuppressive treatment, absolute lymphocyte count,
antiviral therapy, duration of steroid use before the diagnosis
of BKV-HC, and duration from HSCT to the onset of BKV-HC,
did not differ signiﬁcantly between the choreito group and
the nonchoreito group (Tables 1 and 2). However, the he-
maturia grade at the time of diagnosis of BKV-HC was
signiﬁcantly higher in the choreito group than in the non-
choreito group (P ¼ .018) (Table 2). Choreito was adminis-
tered over a median of 5 days after the onset of symptoms
related to BKV-HC (range, 2 to 16 days), and this interval was
not statistically different from that of other treatments
(median, 4 days; range, 1 to 23 days; P ¼ .43) (Table 3). The
urine BKV load before treatment amounted to a median of
2.6  1010 copies/mL (range, 1.3  109 to 6.3  1010 copies/
mL) in children receiving choreito, which was not statisti-
cally different from that in those not receiving choreito
(median, 3.4  1010 copies/mL; range, 8.3  107 to 1.3  1011
copies/mL; P¼ .67) (Table 3). Similarly, the BKV load inwhole
blood before treatment was not statistically different be-
tween the choreito and nonchoreito groups (P¼ .24, Table 3).
In all 14 childrenwith BKV-HC, the duration from the start
of therapy to CR as deﬁned by disappearance of dysuria,
pollakisuria, urinary urgency, and the sensation of residual
urine was signiﬁcantly shorter in the choreito group (me-
dian, 9 days; range, 4 to 17 days) than in the nonchoreito
group (median, 17 days; range, 15 to 66 days; P ¼ .037)
(Table 3, Figure 1A): the odds ratio of choreito versus non-
choreito was .63 (95% conﬁdence interval, .22 to .93; P ¼
.0031). With regard to 11 children with HC graded  II at the
beginning of therapy, the administration of choreito
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N. Kawashima et al. / Biol Blood Marrow Transplant 21 (2015) 319e325322signiﬁcantly shortened the duration from the onset to BKV-
HC grade  I (median, 2 days; range, 2 to 4 days) in com-
parisonwith that in the nonchoreito group (median, 11 days;
range, 5 to 28 days; P ¼ .0043) (Table 3, Figure 1B). The
duration from start of therapy to CR was also signiﬁcantly
shorter in the choreito group (median, 7 days; range, 4 to 17
days) than in the nonchoreito group (median, 20 days; range,
15 to 66 days; P ¼ .048) (Table 3, Figure 1C): here, the odds
ratio of choreito versus nonchoreito was .66 (95% conﬁdence
interval, .14 to .95; P ¼ .0058).
Sequential Analysis of BKV Load after Choreito Treatment
BKV-HCerelated symptoms improved signiﬁcantly earlier
in children receiving choreito, and we studied whether these
earlier improvements were related to the clearance of BKV.
The BKV load in urine and whole blood was monitored after
the diagnosis of BKV-HC in children receiving choreito. The
urine BKV load generally decreased over time. The median
urine BKV load was 1.7  108 copies/mL (range, 2.6  104 to
3.1 1010 copies/mL) 1 month after BKV-HC diagnosis when
all children had achieved CR, and they experienced a statis-
tically signiﬁcant decrease in BKV load since the time of
diagnosis (P ¼ .031; Wilcoxon signed-rank test for paired
samples) (Table 3, Figure 2A). At the time of CR, only 1 of 6
children had a urine BKV load lower than 1.3  106 copies/
mL, which was the median urine BKV load in children with
asymptomatic viruria. The BKV load inwhole blood appeared
stable during the course of BKV-HC, and no signiﬁcant
decrease was observed a month after diagnosis (P ¼ .44)
(Table 3, Figure 2B).
All 6 children eventually ﬁnished taking choreito, and
relapse of HC was not observed, except for in 1 patient who
experienced relapse twice (patient 9). This patient was
diagnosed with idiopathic aplastic anemia and received a
bone marrow transplant from an unrelated donor; however,
the graft was rejected and he underwent haplo-identical
HSCT as the second HSCT. Because he developed chronic
GVHD, he was administered prednisolone, which was
increased during the exacerbation of chronic GVHD and
which may have contributed to the prolonged elevation of
the BKV load. Every time the patient had a relapse of BKV-HC,
he was administered choreito, and his genitourinary symp-
toms resolved within a few days (Supplemental Figure 1).
Safety and Tolerability of Treatment
All children were able to take choreito per os. Notably,
there were no adverse effects due to choreito intake, and
renal function impairment was not observed in children
receiving choreito (Table 3). The reported adverse effects of
choreito include drug allergy and mild gastric discomfort
[14], which were not observed in any of the children. In the
nonchoreito group, 1 patient (patient 3) who received cido-
fovir for BKV infection developed impaired renal function,
possibly resulting from renal toxicity of cidofovir and post-
renal acute kidney injury due to clot retention.
DISCUSSION
Unlike its effect in immunocompetent patients, HC is life
threatening in immunocompromised patients with hemato-
oncological disease, particularly among patients undergoing
HSCT [17]. To our knowledge, prospective studies of the
treatment for BKV-HC are not available, and there are no
standard treatment guidelines for post-HSCT HC. Treatment
modalities are limited, particularly in children, partly owing
to few reports on children receiving pharmaceutical and
Figure 1. Comparison of choreito and nonchoreito treatment for BK virus-associated hemorrhagic cystitis (BKV-HC). The duration from the beginning of therapy to
complete resolution (CR), as deﬁned by the absence of dysuria, pollakisuria, urinary urgency, or the sensation of residual urine, was shorter in the choreito group
(median, 9 days; range, 4 to 17 days) than in the nonchoreito group (median, 17 days; range, 15 to 66 days; P ¼ .037) (A). When comparing children with HC graded 
II, the administration of choreito signiﬁcantly shortened the duration from the onset to BKV-HC grade  I (median, 2 days; range, 2 to 4 days) in comparison with that
in the nonchoreito group (median, 11 days; range, 5 to 28 days) (B). The duration from start of therapy to CR was also signiﬁcantly shorter in the choreito group
(median, 7 days; range, 4 to 17 days) than in the nonchoreito group (median, 20 days; range, 15 to 66 days; P ¼ .048) (C).
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forced diuresis is conducted; however, this is supportive
treatment only without reliable efﬁcacy.
At present, cidofovir is the only commercially available
antiviral agent against BKV, and its efﬁcacy for BKV-HC has
been investigated only in retrospective studies [19-21]. In the
report from the European Group for Blood and Marrow
Transplantation, intravenous or intravesical cidofovir was
administered to 62 patients with BKV-HC [21]. Of the 62
patients, 41 (66%) achieved CR and 8 (13%) had partial
response after cidofovir treatment; however, no improve-
ment or deterioration was observed in 12 patients (19%). CR
is related to clearance of BK viremia in patients with BK
viremia detected at the beginning of treatment, and the
median time to clearance is 37 days (range, 7 to 102 days). Of
57 patients receiving intravenous cidofovir, 17 (30%) experi-
enced renal toxicity. In a pediatric cohort, 19 children
received cidofovir for BKV-HC grade  II [19]. Macroscopic
hematuria resolved in 15 (79%) after a median of 22 days
(range, 9 to 63 days). In 1 patient, HC progressed to grade IV
during cidofovir treatment. Notably, the baseline creatinine
level appeared to be elevated after treatment. AnotherFigure 2. BK virus (BKV) load after choreito treatment. The BKV load before treatme
6.3  1010 copies/mL) and a median of 6.5  102 copies/mL in whole blood (range, 0
(range, 2.6  104 to 3.1 1010 copies/mL) 1 month after BKV-HC diagnosis, and the BKV
rank test, P ¼ .031) (A). The BKV load in whole blood appeared stable during the cours
(Wilcoxon signed-rank test, P ¼ .44) (B).pediatric cohort included 12 children with BKV-HC treated
by intravenous and/or intravesical cidofovir [20]. Themedian
duration of symptoms was 25 days (range, 9 to 73 days) and
no persistent nephrotoxicity was observed. Compared with
cidofovir treatment, children treated with choreito treat-
ment in our study experienced no impairment of renal
function; all patients with BKV-HC achieved CR and BKV-HC
resolved earlier.
Hyperbaric oxygen therapy is another alternative treat-
ment for BKV-HC [11,22]. A retrospective study included 16
patients with BKV-HC grade II (5 patients under 19 years of
age), 15 (94%) of whom achieved CR after a median of 17 days
(range, 4 to 116 days) [11]. In a pediatric cohort of 10 children
with BKV-HC grade  II, 9 (90%) achieved CR after a median
of 15 days (range, 10 to 37 days), including spontaneous
resolution [22]. Hyperbaric oxygen is generally well toler-
ated; however, it requires a high-cost facility and adverse
effects have been reported, including ruptured tympanum.
Other alternative therapies include leﬂunomide and ﬂu-
oroquinolone antibiotics [12]; however, experience is
limited, even in adults [13]. Few reports of leﬂunomide use in
the setting of HSCT are available and its safety has not beennt amounted to a median of 2.6  1010 copies/mL in urine (range, 1.3  109 to
to 9.0  104 copies/mL). The median urine BKV load was 1.7  108 copies/mL
load had signiﬁcantly decreased since the time of diagnosis (Wilcoxon signed-
e of BKV-HC, and no signiﬁcant decrease was observed a month after diagnosis
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contraindicated in children because they cause arthrotoxicity
in juvenile animals and are associated with reversible
musculoskeletal events in both children and adults; there-
fore, they are not recommended in the absence of convincing
evidence.
Choreito is a formula stemming from Japanese traditional
(Kampo) medicine, originally developed from traditional
Chinese medicine; it was the orthodox medicine in Japan
until the 19th century, whenmodernWesternmedicine took
over [14]. Nevertheless, some Kampo formulae are still ofﬁ-
cially registered in the Japanese Pharmacopoeia. Although
Kampo extracts are crude drugs derived from plants, ani-
mals, and minerals, their quality is strictly controlled in
accordance with the Japanese Pharmacopoeia by quantita-
tive analysis of marker components using high-performance
liquid chromatography. Kampo formulae are classiﬁed as
dietary supplements outside Japan and are approved for
marketing by the Food and Drug Administration in the
United States.
Choreito is a crude product from Polyporus umbellatus
sclerotium, Wolﬁporia extensa sclerotium, Alisma orientale
rhizome, aluminum silicate hydrate with silicon dioxide, and
glue. Ergone isolated from P. umbellatus prevented early
renal injury in a rat model of nephropathy [23] and may play
a central role in the effect exerted by choreito. Pollakisuria
was ameliorated in 93% of patients who received choreito for
lower urinary tract symptoms in an open-label, single-arm
study of 30 patients [24]. Choreito was also administered to
patients with urolithiasis for enhancing the evacuation of
stones after extracorporeal shock wave lithotripsy [25]. In
these studies, no severe adverse effects were observed,
suggesting high safety of choreito.
Considering the wide range of indications in genitouri-
nary disorders, choreito may protect epithelial cells irre-
spective of the type of pathogens and thereby be an effective
treatment option for the hemostasis of HC. Although the
precise pathogenesis of BKV-HC remains unclear, urothelial
cells infected with BKV in vitro detached without causing
local cell lysis, which may be associated with the denudation
of the damaged mucosa in patients with BKV-HC [26].
Choreito may protect urothelial cells from detaching, which
may result in a signiﬁcant reduction of the BKV load in urine,
although the whole blood BKV load appears unchanged and
the BKV burden itself is not reduced. Notably, unlike other
antiviral agents or surgical interventions, no adverse effects
were observed during choreito administration, although the
mechanism of action of choreito remains unclear; hence, its
safety cannot be easily predicted.
Our study has some limitations. The small number of
study subjects in this single-center retrospective analysis
may result in bias. Five of 8 subjects in the nonchoreito group
had grade II to III GVHD, whereas 1 out of 6 subjects in the
choreito group had grade IV GVHD. This difference in GVHD
frequency could have been a contributing factor for the dif-
ference in HC severity and BKV clearance, although it was not
statistically different (P ¼ .14) among the 2 groups, possibly
because of the small sample size. Children with concomitant
AdV viruria were included only in the nonchoreito group,
which may explain the longer time before CR in the non-
choreito group. In the present study, HC was signiﬁcantly
more severe in the choreito group than the nonchoreito
group. This difference may represent the difference in pre-
conditioning and donor sources: the choreito group included
more cases of haplo-identical HSCT, whichmay have resultedin intensiﬁed immunosuppression. More severe HC corre-
lates with a longer duration of HC [2]. Nevertheless, the
duration of HC was signiﬁcantly shorter in the choreito
group, which exempliﬁes its effectiveness. Although the
urine BKV load had signiﬁcantly decreased 1 month after
choreito treatment examined by the paired samples, this
decrease could not be compared with that of the nonchoreito
group because of a lack of paired samples in most of the
patients in the nonchoreito group. Thus, the impact of
choreito treatment on the urine BV virus load should be
investigated in a prospective study where the BKV load is
sequentially followed for every study subject.
In conclusion, choreito may be a safe and effective ther-
apy for the hemostasis of late-onset BKV-HC following HSCT,
although it may not decrease the BKV burden. Although its
precise mechanism of hemostasis remains unclear, choreito
may be administered as the ﬁrst-line treatment for post-
HSCT HC. Prospective, randomized studies are warranted to
conﬁrm the efﬁcacy of choreito in the treatment of BKV-HC.
Fundamental research aiming to identify the active in-
gredients and mechanisms of action is also essential.ACKNOWLEDGMENTS
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